Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Non-Current Assets of $1.3 billion for Q1 2026, up 24.73% year-over-year from $1.0 billion in Q1 2025, and up 1.6% quarter-over-quarter from $1.2 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 24.73% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 24.73% YoY), while the FY2025 annual figure was $1.2 billion, up 23.75% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.3 billion in Q1 2026, with the low at $110.7 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $895.3 million (2023), against an average of $734.0 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets surged 286.18% in 2023, then advanced 10.89% in 2025.
- Vertex Pharmaceuticals' Other Non-Current Assets stood at $409.6 million in 2022, then jumped by 118.58% to $895.3 million in 2023, then climbed by 11.62% to $999.3 million in 2024, then increased by 23.75% to $1.2 billion in 2025, then climbed by 1.6% to $1.3 billion in 2026.
- Business Quant data shows VRTX's Other Non-Current Assets at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Bn |
| Mar 31, 2026 | 1.26 Bn |
| Dec 31, 2025 | 1.24 Bn |
| Sep 30, 2025 | 1.10 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 999.30 Mn |
| Sep 30, 2024 | 990.20 Mn |
| Jun 30, 2024 | 915.60 Mn |
| Mar 31, 2024 | 875.70 Mn |
| Dec 31, 2023 | 895.30 Mn |
| Sep 30, 2023 | 475.20 Mn |
| Jun 30, 2023 | 442.70 Mn |
| Mar 31, 2023 | 427.50 Mn |
| Dec 31, 2022 | 409.60 Mn |
| Sep 30, 2022 | 132.50 Mn |
| Jun 30, 2022 | 127.30 Mn |
| Mar 31, 2022 | 110.70 Mn |
| Dec 31, 2021 | 110.80 Mn |
| Sep 30, 2021 | 75.52 Mn |